Search Results - "Reitan, John F."

Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in United States dialysis patients by Stephens, J. Mark, Emerson, Larry C., Spry, Leslie A., Caloyeras, John P., Anderson, Ernest R., Reitan, John F., Ashfaq, Akhtar

“…Objective: Previous research suggests that erythropoiesis stimulating agent (ESA) administration in dialysis is a time-consuming task and switching to less…”
Get full text

Staff Time and Motion Assessment for Administration of Erythropoiesis-Stimulating Agents: A Two-Phase Pilot Study in Clinical Oncology Practices by Reitan, John F., van Breda, Arletta, Corey-Lisle, Patricia K., Shreay, Sanatan, Cong, Ze, Legg, Jason

“…Background Erythropoiesis-stimulating agents (ESAs) are used for the management of anaemia in patients with non-myeloid malignancies where anaemia is due to…”
Get full text

The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA) by Reitan, John F, Kudrik, Fred J, Fox, Kayleen, van Breda, Arletta, Shreay, Sanatan, Corey-Lisle, Patricia K

“…The objective is to measure the burden of blood transfusion of Packed Red Blood Cells (PRBCs) in patients with chemotherapy-induced anemia (CIA) on the…”
Get more information

Erythropoiesis-Stimulating Agent (ESA) Practice Patterns in Patients with Chemotherapy-Induced Anemia (CIA) Treated at Hospital Oncology Clinics by Reitan, John F., van Breda, Arletta, Shreay, Sanatan, Corey-Lisle, Patricia K., Cong, Ze

“…Objectives To characterize erythropoiesis-stimulating agent (ESA) usage initiated in hospital outpatient oncology centers that employ weekly (QW) and…”
Get full text

Impact of Long-Acting Growth Factors on Practice Dynamics and Patient Satisfaction by Beveridge, Roy A., Rifkin, Robert M., Moleski, Ronald J., Milkovich, Gary, Reitan, John F., Paivanas, Thomas A., Jacobs, R. Jake

“…Objective. To quantify time expended, patient satisfaction, and econometrics associated with short‐acting (sargramostim, epoetin alfa) and long‐acting…”
Get full text

Comparative Safety of Filgrastim versus Sargramostim in Patients Receiving Myelosuppressive Chemotherapy by Milkovich, Gary, Moleski, Ronald J., Reitan, John F., Dunning, David M., Gibson, Gene A., Paivanas, Thomas A., Wyant, Susan, Jacobs, R. Jake

“…Study Objective. To compare rates of adverse events with filgrastim versus sargramostim when given prophylactically to patients receiving myelosuppressive…”
Get full text

Erythropoiesis-Stimulating Agent (ESA) Practice Patterns in Patients With Chemotherapy-Induced Anemia (CIA) Treated at Hospital Oncology Clinics by Reitan, John F, van Breda, Arletta, Shreay, Sanatan, Corey-Lisle, Patricia K, Cong, Ze

“…OBJECTIVESTo characterize erythropoiesis-stimulating agent (ESA) usage initiated in hospital outpatient oncology centers that employ weekly (QW) and…”
Get full text

Impact of long-acting growth factors on practice dynamics and patient satisfaction: Darbepoetin alfa in the management of chemotherapy-induced anemia by BEVERIDGE, Roy A, RIFKIN, Robert M, MOLESKI, Ronald J, MILKOVICH, Gary, REITAN, John F, PAIVANAS, Thomas A, JACOBS, R. Jake

Get full text